Previous anti-EGFR trials in unselected patients with gastroesophageal adenocarcinoma
(GEA) were resoundingly negative. We identified EGFR amplification in 5%(19/363) of …

Background Approximately 50% of gastric adenocarcinomas belong to a molecular
subgroup characterised by chromosomal instability and a strong association with the …

LBA4000 Background: EGFR overexpression occurs in 27-50% of esophagogastric
adenocarcinomas (OGA), and correlates with poor prognosis. The REAL3 trial evaluated the …

Background EGFR overexpression occurs in 27–55% of oesophagogastric
adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the …

Objective Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-
selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients …

Cancers of the esophagus and stomach present a major health burden worldwide. In the
past 30 years we have witnessed some interesting shifts in terms of epidemiology of …

Background Epidermal growth factor receptor (EGFR) and hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition (MET) pathways, which promote tumour growth …

Gastroesophageal (GE) adenocarcinomas are highly lethal malignancies and despite
multiple chemotherapy options, 5-year survival rates remain dismal. Chemotherapy is the …

Esophagogastric cancer represents a significant global health problem, with most patients
presenting with advanced-stage disease and consequently with a poor prognosis …

Gastroesophageal adenocarcinoma (GEA) is a lethal disease where targeted therapies,
even when guided by genomic biomarkers, have had limited efficacy. A potential reason for …